For example, HER2-positive patients receive HER2-targeted antibody or small-molecule inhibitor treatment combined with chemotherapy, and patients with hormone receptor-positive or triple-negative breast cancer (TNBC) receive endocrine therapy (ET) and chemotherapy, respectively7. Here, ERBB2 is linked to triple-negative breast carcinoma.